MR. FERNANDO ANDRES PARRAGA PA-C
Prescription History 1821746934
Physician Assistant - Surgical in Sugar Land, TX
Quality Rating: 82.38 out of 100 score
NPI Status: Active since March 17, 2022
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. FERNANDO ANDRES PARRAGA PA-C, an active Surgical specialist practicing in Sugar Land, TX. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 49 documented patient claims. Among these therapy options, the most frequently utilized medication is Meloxicam, which accounts for 34 claims alone.
Doxycycline Monohydrate
Generic Formulation: Doxycycline MonohydrateSpecialty: Physician AssistantProvider Avg Cost Per Claim
$7.50
State Avg Cost Per Claim
$22.91
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A plant family of the order Dipsacales, subclass Asteridae, class Magnoliopsida. Members of this family are sometimes classified in CAPRIFOLIACEAE.
This medication is used to treat a certain type of skin condition called rosacea. It helps to reduce the number of pimples and bumps on the face, but it may not decrease redness. It works by reducing skin inflammation caused by rosacea. Although doxycycline belongs to the class of antibiotics known as tetracyclines, this product does not work as an antibiotic because it does not stop the growth of bacteria. Do not use this product to treat any infection, including viral infections (such as the common cold, flu). Use this medication only as prescribed by your doctor.
Meloxicam
Generic Formulation: MeloxicamSpecialty: Physician AssistantProvider Avg Cost Per Claim
$3.82
State Avg Cost Per Claim
$6.87
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.
Meloxicam is used to help relieve moderate to severe pain. Meloxicam is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation. This effect helps to decrease swelling or pain.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. FERNANDO ANDRES PARRAGA PA-C provides transparency into local medical care patterns within Sugar Land, TX.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Surgical** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
